ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 5.9% – Here’s Why

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) traded up 5.9% during trading on Wednesday . The stock traded as high as $6.07 and last traded at $6.06. 689,919 shares changed hands during trading, a decline of 61% from the average session volume of 1,751,661 shares. The stock had previously closed at $5.72.

Key ARS Pharmaceuticals News

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Neutral Sentiment: Several firms, including Kaplan Fox, Faruqi & Faruqi, Levi & Korsinsky, and Rosen, reminded investors that October 5, 2026 is the deadline to seek appointment as lead plaintiff in the pending federal securities lawsuit. These announcements largely repeat previously reported information rather than introduce a new operational development. Kaplan Fox class action deadline notice
• Negative Sentiment: The litigation alleges that ARS Pharmaceuticals and Chief Commercial Officer Eric Karas misled investors about the timing of expanded CVS Caremark coverage for neffy, the company’s needle-free epinephrine product. The allegations relate to a reported single-session decline of 23.9% in SPRY shares after the market received adverse information. The claims have not been proven, but the lawsuit adds legal, reputational, and potential financial risk. Levi and Korsinsky ARS lawsuit notice
• Negative Sentiment: The unusually large number of investor-law-firm solicitations may keep attention focused on the company’s disclosure practices and neffy reimbursement outlook. Investors should monitor ARS’s responses, court developments, and any updates regarding CVS Caremark coverage. Faruqi and Faruqi ARS investor notice

Analyst Ratings Changes

SPRY has been the topic of several recent analyst reports. Leerink Partners lowered their price target on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Thursday, June 25th. Weiss Ratings downgraded ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Wall Street Zen raised shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Cantor Fitzgerald boosted their target price on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 28th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $28.20.

ARS Pharmaceuticals Stock Up 5.9%

The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. The firm has a market cap of $602.67 million, a price-to-earnings ratio of -2.78 and a beta of 0.98. The stock has a 50-day moving average of $7.07 and a 200-day moving average of $8.08.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. The firm had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. Sell-side analysts predict that ARS Pharmaceuticals, Inc. will post -1.9 EPS for the current fiscal year.

Insider Activity at ARS Pharmaceuticals

In related news, insider Alexander A. Fitzpatrick sold 3,355 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $33,550.00. Following the transaction, the insider owned 90,910 shares in the company, valued at $909,100. The trade was a 3.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the transaction, the insider directly owned 12,176 shares in the company, valued at $121,760. The trade was a 67.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 33.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in ARS Pharmaceuticals by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock worth $56,000 after purchasing an additional 982 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of ARS Pharmaceuticals by 3.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company’s stock valued at $596,000 after purchasing an additional 1,234 shares during the last quarter. ProShare Advisors LLC grew its position in shares of ARS Pharmaceuticals by 11.3% during the fourth quarter. ProShare Advisors LLC now owns 15,139 shares of the company’s stock valued at $176,000 after purchasing an additional 1,532 shares in the last quarter. FAS Wealth Partners Inc. increased its holdings in shares of ARS Pharmaceuticals by 0.9% in the fourth quarter. FAS Wealth Partners Inc. now owns 202,407 shares of the company’s stock worth $2,358,000 after purchasing an additional 1,787 shares during the last quarter. Finally, Osaic Holdings Inc. increased its holdings in shares of ARS Pharmaceuticals by 52.8% in the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock worth $91,000 after purchasing an additional 1,803 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.